Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22.

2.

Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.

Werner MT, Zhao C, Zhang Q, Wasik MA.

Blood. 2017 Feb 16;129(7):823-831. doi: 10.1182/blood-2016-05-717793. Epub 2016 Nov 22. Review.

3.

Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.

Rodig SJ, Shapiro GI.

Curr Opin Investig Drugs. 2010 Dec;11(12):1477-90. Review.

PMID:
21154129
4.

Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.

Drexler HG, Gignac SM, von Wasielewski R, Werner M, Dirks WG.

Leukemia. 2000 Sep;14(9):1533-59. Review.

PMID:
10994999
5.

Pathobiology of ALK+ anaplastic large-cell lymphoma.

Amin HM, Lai R.

Blood. 2007 Oct 1;110(7):2259-67. Epub 2007 May 22. Review.

6.

Anaplastic lymphoma kinase in human cancer.

Barreca A, Lasorsa E, Riera L, Machiorlatti R, Piva R, Ponzoni M, Kwee I, Bertoni F, Piccaluga PP, Pileri SA, Inghirami G; European T-Cell Lymphoma Study Group.

J Mol Endocrinol. 2011 Jul 4;47(1):R11-23. doi: 10.1530/JME-11-0004. Print 2011 Aug. Review.

PMID:
21502284
7.

Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.

Foyil KV, Bartlett NL.

Cancer J. 2012 Sep-Oct;18(5):450-6. Review.

PMID:
23006951
8.

Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma.

Tabbò F, Ponzoni M, Rabadan R, Bertoni F, Inghirami G; European T-cell Lymphoma Study Group.

Curr Opin Hematol. 2013 Jul;20(4):374-81. doi: 10.1097/MOH.0b013e3283623c07. Review.

9.

Novel ALK inhibitors in clinical use and development.

Iragavarapu C, Mustafa M, Akinleye A, Furqan M, Mittal V, Cang S, Liu D.

J Hematol Oncol. 2015 Feb 27;8:17. doi: 10.1186/s13045-015-0122-8. Review.

10.

The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability.

Lobello C, Bikos V, Janikova A, Pospisilova S.

Cancers (Basel). 2018 Mar 5;10(3). pii: E64. doi: 10.3390/cancers10030064. Review.

11.

Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy.

Ardini E, Magnaghi P, Orsini P, Galvani A, Menichincheri M.

Cancer Lett. 2010 Dec 28;299(2):81-94. doi: 10.1016/j.canlet.2010.09.001. Epub 2010 Oct 8. Review.

PMID:
20934803
12.

Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers.

Alshareef A.

Cancers (Basel). 2017 Oct 28;9(11). pii: E148. doi: 10.3390/cancers9110148. Review.

13.

Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.

Webb TR, Slavish J, George RE, Look AT, Xue L, Jiang Q, Cui X, Rentrop WB, Morris SW.

Expert Rev Anticancer Ther. 2009 Mar;9(3):331-56. doi: 10.1586/14737140.9.3.331. Review.

14.

PAX-5 Positivity in Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma: A Case Report and Review of Literature.

Arun I, Roy P, Arora N, Bhave SJ, Nair R, Chandy M.

Int J Surg Pathol. 2017 Jun;25(4):333-338. doi: 10.1177/1066896916683447. Epub 2016 Dec 26. Review.

PMID:
28013563
15.

From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL).

Werner MT, Zhang Q, Wasik MA.

Cancers (Basel). 2017 Oct 16;9(10). pii: E138. doi: 10.3390/cancers9100138. Review.

16.

Anaplastic large cell lymphoma in paediatric and young adult patients.

Turner SD, Lamant L, Kenner L, Brugières L.

Br J Haematol. 2016 May;173(4):560-72. doi: 10.1111/bjh.13958. Epub 2016 Feb 23. Review.

PMID:
26913827
17.

The anaplastic lymphoma kinase as an oncogene in solid tumors.

Voena C, Peola S, Chiarle R.

Front Biosci (Schol Ed). 2015 Jun 1;7:269-82. Review.

PMID:
25961702
18.

Adult systemic anaplastic large-cell lymphoma: recommendations for diagnosis and management.

Bennani-Baiti N, Ansell S, Feldman AL.

Expert Rev Hematol. 2016;9(2):137-50. doi: 10.1586/17474086.2016.1122514. Epub 2015 Dec 11. Review.

19.

Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma.

Wallace GC 4th, Dixon-Mah YN, Vandergrift WA 3rd, Ray SK, Haar CP, Mittendorf AM, Patel SJ, Banik NL, Giglio P, Das A.

Metab Brain Dis. 2013 Sep;28(3):355-66. doi: 10.1007/s11011-013-9401-7. Epub 2013 Apr 2. Review.

20.

Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond.

Prokoph N, Larose H, Lim MS, Burke GAA, Turner SD.

Cancers (Basel). 2018 Mar 30;10(4). pii: E99. doi: 10.3390/cancers10040099. Review.

Supplemental Content

Support Center